- AU$9.11m
- AU$81.41m
- AU$17.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.44 | ||
| Price to Tang. Book | 1.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.59 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -570.14% | ||
| Return on Equity | -168.11% | ||
| Operating Margin | -252.73% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.91 | 4.33 | 6.41 | 13.78 | 17.52 | n/a | n/a | 49.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cann Group Limited is an Australia-based company that is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the group, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. It operates through cultivation of the medicinal cannabis segment. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research, cultivation, and good manufacturing practices (GMP) manufacturing facilities are in Melbourne, and a cultivation and GMP manufacturing facility is near Mildura, Victoria.
Directors
- Allan Mccallum NEC
- Peter Crock CEO
- Deborah Ambrosini CFO
- Steven Notaro OTH
- Geraldine Farrell SEC
- Jenni Pilcher DRC
- John Sharman DRC
- Geoffrey Pearce NID
- Douglas Rathbone NID (70)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 30th, 2015
- Public Since
- May 4th, 2017
- No. of Employees
- 40
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 536,086,077
- Address
- Ground Floor, MELBOURNE, 3207
- Web
- https://www.canngrouplimited.com/
- Phone
- +61 390957088
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for CAN
Similar to CAN
Apiam Animal Health
Australian Stock Exchange - SEATS
Artrya
Australian Stock Exchange - SEATS
Australian Clinical Labs
Australian Stock Exchange - SEATS
Careteq
Australian Stock Exchange - SEATS
CLEO Diagnostics
Australian Stock Exchange - SEATS
FAQ
What is the Cann share price?
As of Today at 19:47 UTC, shares in Cann are trading at AU$0.02. This share price information is delayed by 15 minutes.
How has the Cann share price performed this year?
Shares in Cann last closed at AU$0.02 and the price had moved by -71.02% over the past 365 days. In terms of relative price strength the Cann share price has underperformed the ASX All Ordinaries Index by -71.46% over the past year.
What are the analyst and broker recommendations for Cann?
The overall consensus recommendation for Cann is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cann dividend yield?
Cann does not currently pay a dividend.
Does Cann pay a dividend?
Cann does not currently pay a dividend.
When does Cann next pay dividends?
Cann does not currently pay a dividend.
How do I buy Cann shares?
To buy shares in Cann you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cann?
As of the previous close price of AU$0.02, shares in Cann had a market capitalisation of AU$9.11m.
Where are Cann shares listed?
Here are the trading details for Cann:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CAN
What kind of share is Cann?
Based on an overall assessment of its quality, value and momentum Cann is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cann share price forecast for 2025?
The analyst consensus target price for shares in Cann is AU$1.08. That is 6252.94% above the last closing price of AU$0.02.
Analysts covering Cann currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Cann share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cann. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -58.56%.
As of the last closing price of AU$0.02, shares in Cann were trading -53.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cann PE Ratio?
The Cann PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cann?
Cann's management team is headed by:
- Allan Mccallum - NEC
- Peter Crock - CEO
- Deborah Ambrosini - CFO
- Steven Notaro - OTH
- Geraldine Farrell - SEC
- Jenni Pilcher - DRC
- John Sharman - DRC
- Geoffrey Pearce - NID
- Douglas Rathbone - NID